Table 4 Overview of reported late toxicities in EBRT for localized prostate cancer
Study (reference) | Patients | Prescription dose | Technique | Posterior margin (other) | GI toxicity (%) | GU toxicity (%) | Grading scale | Follow-up | ||
|---|---|---|---|---|---|---|---|---|---|---|
(n) | (Gy) | (cm) | Grade 2 | Grade 3 | Grade 2 | Grade 3 | (months) | |||
Present study | 261 | 78–86 | 3D-CRT | 0.5 (0.5) | 1.9 | 0.4 | 10.3 | 1.1 | CTCAE4.0 | 61 |
RTOG9406 (8) | 167 | 79.2 | 3D-CRT | 0.5–1.0 | 11–14, Grade 2/3 | 18–21, Grade 2/3 | RTOG | 102–110 | ||
220 | 78 | 25–26 | 23–28 | 71–73 | ||||||
Ikeda et al. [24] | 150 | 74 | 3D-CRT | 0.6 (0.9) | 5.5, Grade 2/3 | 2.9, Grade 2/3 | RTOG/EORTC | 89 | ||
Kuban et al. [12] | 151 | 78 | 3D-CRT | - (box four field) | 19 | 7 | 7 | 3 | RTOG/LENT | 61 |
Spratt et al. [20] | 1002 | 86.4 | IMRT | 0.6 (1.0) | 4.4, Grade 2/3 | 21.1, Grade 2/3 | CTCAE4.0 | 63 | ||
Eade et al. [21] | 216 | 74–78 | IMRT | 0.5–0.6 (0.8) | 2.4 | 0 | 3 | 0.5 | RTOG | 48 |
De Meerleer et al. [22] | 133 | 74–76 | IMRT | 0.7 (1.0) | 17 | 1 | 19 | 3 | RTOG | 36 |